GnRH-II: reproductive and appetite-signaling brain peptide
A natural brain peptide found in nearly all vertebrates, including humans, that links food availability to reproductive readiness and regulates sexual behavior; used as a research tool, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
GnRH-II (also called chicken GnRH-II, or cGnRH-II) is a 10-residue neuropeptide found in the brain and peripheral tissues of virtually every jawed vertebrate — from fish and amphibians through birds, marsupials, and primates, including humans. It is the second of at least two distinct forms of gonadotropin-releasing hormone (GnRH) that exist within a single species. Unlike the classical GnRH-I, which drives the pituitary release of the reproductive hormones LH and FSH, GnRH-II appears to act predominantly as a neuromodulator: it links energy availability to reproductive readiness, regulates sexual behavior, and exerts direct effects on peripheral reproductive tissues. It is not an approved drug but is widely studied as a research tool for probing GnRH receptor biology and as a prototype for novel GnRH-II–selective analogs in oncology.
The stored sequence HWSHGWYPG represents residues 2–10 of the natural decapeptide. The complete native peptide is pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH₂: it carries a pyroglutamate cap at the N-terminus and a C-terminal amide (-NH₂), both of which are absent from the raw stored letters. These modifications are pharmacologically essential — they protect the termini from exopeptidase cleavage and contribute to GnRH receptor binding.
History
The existence of a second hypothalamic factor with gonadotropin-releasing activity in birds was first established by Miyamoto and colleagues in 1984, who isolated a novel peptide from approximately 10,000 chicken hypothalami and determined its primary sequence (Miyamoto et al., Proceedings of the National Academy of Sciences 1984). The peptide differed from the previously characterised mammalian GnRH-I (then known as LHRH) at positions 5, 7, and 8 — substitutions His⁵, Trp⁷, and Tyr⁸ — and was named chicken GnRH-II (cGnRH-II) to distinguish it from the chicken form of GnRH-I.
What made subsequent decades of comparative endocrinology remarkable was the discovery that cGnRH-II is universally present across jawed vertebrate classes with no sequence variation whatsoever. The same decapeptide found in chicken hypothalamus in 1984 is also present in teleost fish, amphibians, reptiles, marsupials, and primates. This extreme degree of structural conservation — a 10-residue peptide essentially unchanged across more than 500 million years of vertebrate evolution — argued strongly that GnRH-II must carry out functions that evolution could not afford to let vary.
Interest expanded further when the peptide and its receptor were detected in mammalian peripheral tissues, including prostate, ovary, kidney, and bone marrow in humans, suggesting roles well beyond central reproductive neuroendocrinology.
What it does
GnRH-II binds to GnRH receptors on target cells and activates downstream signaling. Its best-characterised roles are in three areas:
Linking energy status to reproductive behavior. In mammals, GnRH-II concentrations in specific brain regions fall during food restriction and are restored within 90 minutes of refeeding. In musk shrews (Suncus murinus), which retain a functional type-2 GnRH receptor (GnRHR2), central infusion of GnRH-II rapidly enhances female sexual receptivity while simultaneously suppressing short-term food intake — effects that GnRH-I does not replicate (Temple, Millar & Rissman, Endocrinology 2003; Schneider & Rissman, Integrative and Comparative Biology 2008). This positions GnRH-II as a permissive signal that coordinates reproductive effort with periods of sufficient energetic resources.
Direct action in peripheral reproductive tissues. GnRH-II and its receptor (GnRHR2) are expressed in peripheral tissues including the testis, ovary, endometrium, and placenta. In porcine Leydig cells, GnRH-II directly stimulates testosterone secretion independent of LH, establishing an autocrine/paracrine regulatory loop for steroidogenesis (Desaulniers and colleagues, Frontiers in Endocrinology 2017). This is distinct from the classical hypothalamic–pituitary–gonadal (HPG) axis pathway that GnRH-I mediates via pituitary gonadotropes.
Antiproliferative effects in reproductive cancers. GnRH-II and synthetic GnRH-II analogs inhibit proliferation of human endometrial, ovarian, and breast cancer cell lines in vitro, and these effects are reported to be more potent than equimolar doses of GnRH-I agonists such as triptorelin. Antagonistic analogs of GnRH-II induce apoptosis in these cancer cell lines through activation of the stress-activated kinases p38 and JNK and induction of proapoptotic protein Bax, effects that are independent of the type-1 GnRH receptor (GnRHR1). Tumor growth was inhibited in xenograft mouse models carrying human endometrial and ovarian cancer cells.
Evidence
- Human: GnRH-II peptide and mRNA have been detected in human brain tissue and peripheral organs including prostate, ovary, kidney, and bone marrow. The type-2 GnRH receptor gene (GNRHR2) is present in the human genome but contains a frameshift mutation and premature stop codon, making a full seven-transmembrane receptor nonfunctional in humans; whether an alternative translation product with partial transmembrane structure retains any activity remains unresolved. No human clinical trials with GnRH-II as a therapeutic agent have been registered. Its behavioral and metabolic functions in humans remain inferred from the high sequence conservation and receptor expression data rather than from interventional studies.
- Animal: The most informative mammalian model is the musk shrew, which retains intact GnRH-II/GnRHR2 signaling. Studies in this species demonstrated that GnRH-II infusion enhances mating behavior and inhibits food intake, and that food restriction reduces GnRH-II mRNA and peptide levels in multiple brain nuclei (Temple et al. 2003). In porcine models, transgenic reduction of GnRHR2 expression impaired testicular development and lowered testosterone concentrations (Desaulniers et al. 2017). In nude mice carrying human cancer xenografts, GnRH-II antagonist analogs inhibited tumor growth.
- In vitro: GnRH-II reduces proliferation of human endometrial, ovarian, and breast cancer cell lines in dose- and time-dependent fashion. Antagonistic analogs activate p38/JNK-mediated apoptosis via a non-GnRHR1 pathway, implicating GnRHR2 or another receptor subtype. GnRHR2 signaling through this route produces sustained ERK1/2 and p38 MAPK activation — a distinct profile compared to GnRHR1's transient ERK and c-Src pattern (Desaulniers et al. 2017).
Known effects
- Reproductive behavior facilitation — Preclinical (musk shrew); facilitates sexual receptivity under energy-restricted conditions
- Food intake suppression — Preclinical (musk shrew); acute central infusion reduces food intake
- Testicular steroidogenesis — Preclinical (porcine); direct LH-independent stimulation of testosterone from Leydig cells
- Antiproliferative / pro-apoptotic in reproductive cancers — In vitro and in vivo (xenograft); endometrial, ovarian, and breast cancer cell lines; more potent than GnRH-I agonists in these models
- Immune modulation — Mechanistic only; GnRH-family peptides including GnRH-II are implicated in hypothalamic–immune crosstalk (Quintanar et al., Frontiers in Integrative Neuroscience 2013)
Mechanism
GnRH-II is a class A GPCR ligand acting at GnRH receptors. The canonical GnRH receptor (GnRHR1, also the target of GnRH-I agonists and antagonists used clinically) can be activated by GnRH-II, though with different receptor kinetics than GnRH-I. The second receptor, GnRHR2, shows only 40–42% sequence homology with GnRHR1 and retains a 52-amino acid cytoplasmic C-terminal tail that GnRHR1 lacks. This tail drives rapid receptor desensitization and dynamin-dependent internalization upon GnRH-II binding — a kinetics profile distinct from the slow desensitization of GnRHR1. GnRHR2 activates sustained ERK1/2 and p38 MAPK signaling rather than the transient ERK and c-Src activation of GnRHR1, generating a divergent intracellular program despite shared GPCR architecture.
In most mammals, including cattle, sheep, and cats, the GNRH2 or GNRHR2 gene harbors inactivating coding errors, presumably because these species lost selective pressure to maintain the system. In humans, the GNRHR2 gene contains a frameshift and premature stop codon. Non-human primates (marmoset) and musk shrews retain functional GnRHR2. This pattern of gene loss across mammals — alongside the remarkable evolutionary conservation of the peptide's own sequence — is a source of ongoing debate about what GnRH-II's ancestral role was and whether cryptic human GnRHR2 function persists through alternative translation.
GnRH-II differs from GnRH-I at three positions: His⁵, Trp⁷, and Tyr⁸ (versus Tyr⁵, Leu⁷, and Arg⁸ in mammalian GnRH-I). These substitutions shift receptor selectivity, with GnRH-II showing preferential affinity for GnRHR2 over GnRHR1 in species where both receptors are functional. In species where only GnRHR1 is available, GnRH-II can still activate it, but the downstream signaling and behavioral outputs differ from GnRH-I (Tukun et al., Molecules 2017).
The pharmacoperone concept has been applied to GnRH receptors: misfolded GnRHR mutants can be pharmacologically chaperoned back to the cell surface using small molecules, with implications for understanding GnRH receptor trafficking generally (Conn et al., Frontiers in Endocrinology 2011).
Open questions
- Whether any functionally relevant translation product is produced from human GNRHR2 despite its premature stop codon, and if so, what its signaling profile and tissue distribution are
- Whether GnRH-II plays a role in human reproductive behavior or energy homeostasis analogous to its function in musk shrews
- Selectivity requirements for GnRH-II–based anticancer analogs: whether their antiproliferative effects are mediated by GnRHR2, GnRHR1, or an as-yet uncharacterised receptor subtype
- Crystal or cryo-EM structure of GnRHR2 bound to GnRH-II not solved
- Whether the immune-modulatory actions of GnRH-II peptides observed in hypothalamic–immune studies have therapeutic relevance
Related peptides
- Leuprolide (/card/pep-04422): GnRH-I superagonist analog in clinical use for androgen deprivation therapy in prostate cancer, endometriosis, and central precocious puberty; D-Leu⁶ substitution gives it high GnRHR1 affinity and enzymatic stability (Hoda et al., Expert Opinion on Pharmacotherapy 2017). One of the clinical benchmarks against which GnRH-II analog antiproliferative potency is measured in preclinical cancer studies.
- Triptorelin (/card/pep-10602): another GnRH-I superagonist (D-Trp⁶) acting through GnRHR1; FDA-approved for prostate cancer and central precocious puberty. GnRH-II's antiproliferative effects in cancer cell lines exceed those of triptorelin at equimolar doses in preclinical models.
- GnRH-(1–5): a metabolic fragment of GnRH-I (pentapeptide QHWSY) that transactivates EGFR through an orphan GPCR distinct from GnRHR1, with effects demonstrated in Ishikawa human endometrial cells (Cho-Clark et al., Molecular Endocrinology 2014) — evidence that the GnRH family generates biologically active fragments with receptor targets beyond GnRHR1.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the extra tryptophan in GnRH-II be why it behaves so differently from its close cousin GnRH-I?
If true, researchers could design trimmed-down versions of GnRH-II that hit only the cancer-relevant receptor, potentially opening a cleaner path to treatments that avoid hormonal side effects.
Does GnRH-II flip different internal switches in the same receptor that GnRH-I uses, producing different effects in the body?
If GnRH-II selectively activates only certain cellular pathways, drugs designed on its scaffold might one day control appetite and reproductive readiness more independently, a possible route to helping patients with fertility problems tied to eating conditions.
Does the middle part of GnRH-II hold on to its receptor even after the protective end-caps are stripped off?
If GnRH-II works without its caps, simpler and cheaper synthetic versions could be made for research or drug development, removing a manufacturing hurdle.
If you replace the natural protective tip on GnRH-II with a tougher synthetic version, does the peptide last longer in blood?
If a sturdier cap slows breakdown, it could help turn a short-lived research molecule into a longer-acting candidate, though other weak spots in the peptide would likely also need fixing.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9696541428565979 | boltz-2 |
| ranking score | 0.8279194235801697 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10601,
sequence = {HWSHGWYPG},
target = {gnrhr},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}